BF-2T (5MG)

BF-2T, the dual-incretin (GLP-1 + GIP receptor) research analog from the tirzepatide class, supplied by BioFusion as a vacuum-sealed lyophilized vial of 5mg for dual-receptor incretin-biology research.

Research context

BF-2T is the tirzepatide-class dual-incretin research analog (GLP-1R + GIPR co-agonist). The dual-incretin class has been the fastest-growing reference-peptide research segment of 2024-2025, displacing single-receptor GLP-1 analogs in many comparative-chemistry panels.

Synthesis & documentation

Produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility. Each lot is verified for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), moisture (Karl Fischer), and counter-ion (ion chromatography). Compare directly with our BF-1S single-incretin reference and BF-3R triple-incretin reference.

Storage & handling

Lyophilized BF-2T is stable at −20 °C for the printed shelf life. After reconstitution, the standard 14-day-at-2-8 °C reference window applies; avoid freeze-thaw cycling.

Why BioFusion

The dual-incretin segment has attracted significant counterfeiting since the tirzepatide patent landscape opened in research-supply markets. BioFusion’s BF-2T reference is verified by LC-MS for the correct molecular weight (no truncation, no incorrect coupling), with HPLC-purity ≥99.0% confirmed on every lot. Bulk discounts at three+ vials; members save 25% on every order plus complimentary U.S. shipping for 365 days.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.